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Breast cancer patients who have undergone curative surgery and
show no evidence of disease in the axillary lymph nodes or at
distant sites have a recurrence rate as high as 30–40% over 5 to 20
years (Giuliano et al, 1994, 1997; Hellman, 1994). Currently,
primary tumour pathologic factors are more useful in predicting
which patients are at potential risk of regional lymph node metas-
tases rather than those who will go on to develop systemic disease
(Giuliano et al, 1994, 1995; Barth et al, 1997). The John Wayne
Cancer Institute pioneered the SLN dissection procedure for breast
cancer, and has demonstrated that the SLN accurately predicts the
histopathologic status of the axillary basin in breast cancer
patients, thereby allowing a more focused histopathological
analysis (Giuliano et al, 1994, 1995, 1997). 
If the SLN does not contain metastases by haematoxylin and
eosin staining (H&E) or by immunohistochemistry staining (IHC),
the chance of a non-SLN from the same axillary basin containing
breast cancer cells, by H&E or IHC alone, is less than 1%
(Giuliano et al, 1997). Serial sectioning of the SLN, along with
examination by IHC and reverse transcriptase-polymerase chain
reaction (RT-PCR), provides a powerful tool for improving staging
of the axillary basin in breast cancer patients. 
RT-PCR has previously been used as a molecular approach to
the detection of occult metastatic tumour cells in the axillary
lymph nodes, bone marrow, and blood of breast cancer patients
(Datta et al, 1994; Schoenfeld et al, 1994; Burchill et al, 1995;
Hoon et al, 1995a; Mori et al, 1995; Noguchi et al, 1996; Novaes
et al, 1997; Yun et al, 1997; Zippelius et al, 1997; Bostick et al,
1998a). Previous reports have demonstrated the detection of occult
metastases in lymph nodes by RT-PCR using carcinoembryonic
antigen (CEA), cytokeratin-19 (CK-19), or mucin-1 (MUC-1) as
messenger RNA (mRNA) markers (Schoenfeld et al, 1994; Mori
et al, 1995; Noguchi et al, 1996; Bostick et al, 1998a). However, it
has been shown, by our laboratory and others, that CEA, CK-19,
and MUC-1 mRNA transcripts are present in normal epithelial
cells, non-cancer cells of blood, normal lymph nodes, and normal
bone marrow (Bostick et al, 1998a, 1998b, 1998c; Brugger et al,
1999; Lambrechts et al, 1999; Moinfar et al, 1999; Zeng et al,
1999; Xu et al, 2000). The rather frequent expression of these
markers by non-cancer cells limits the potential clinicopatholog-
ical utility and tumour specificity of these mRNA markers for
detecting occult breast cancer micrometastasis (Schoenfeld et al,
1994; Hoon et al, 1995a; Bostick et al, 1998a). 
The ideal mRNA tumour marker is one that is specifically
expressed in cancer cells, but not in the non-cancer cells of the
tissue or fluid being assessed. The MAGE-A3 gene is a unique
tumour mRNA marker in that it is not expressed in normal tissues
except in the placenta and male germ cells (van der Bruggen et al,
1991; Gaugler et al, 1994; Chi et al, 1997; Bostick et al, 1999).
The MAGE-A3 gene belongs to a family of more than 12 closely
related genes (MAGE-A) located on chromosome X (Oaks et al,
1994). Moreover, the MAGE-A gene proteins and peptides are
immunogenic, and can induce cytotoxic T lymphocytes and anti-
bodies in patients (van der Bruggen et al, 1991; Gaugler et al,
1994; Hoon et al, 1995c; Okamoto et al, 1997). Although origi-
nally identified as a melanoma antigen, the MAGE-A3 gene is
commonly expressed in various tumours of epithelial origin,
including breast, lung, and colorectal carcinomas (van der
Bruggen et al, 1991; Gaugler et al, 1994; Russo et al, 1995; Mori
et al, 1996; Fujie et al, 1997; Bostick et al, 1999). 
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Earlier diagnosis of breast cancer, and prediction of recur-
rence, are 2 critical clinical interventions that may help prolong
overall survival. Breast cancer is known to frequently metasta-
size to the regional tumour-draining lymph nodes (Giuliano et al,
1994; Hellman, 1994; Barth et al, 1997). Additionally, it is well
documented that breast cancer cells spread haematogenously to
bone marrow and other organs (Giuliano et al, 1994; Hellman,
1994). However, more than 30% of breast cancer patients with
no evidence of disease metastatic to their lymph nodes, or to
other distant sites at the time of initial diagnosis, will subse-
quently relapse and die of their disease. These patients are
assumed to have subclinical disease that was undetected in the
axillary nodes, and/or to have systemic disease that was other-
wise undetected at the time of presentation. A molecular assay
that can aid in the detection of occult metastatic cells in the
tumour-draining lymph nodes may identify a sub-group of
patients at high risk of systemic disease relapse, and may
possibly be used for stratification of these patients into adjuvant
therapy protocols. Moreover, the confirmation of a specific
tumour’s expression of immunogenic molecular markers, such as
MAGE-A3, may identify patients who might benefit from
targeted adjuvant immunotherapy. To this end, a reliable, sensi-
tive and specific RT-PCR assay could help to improve staging of
the axillary basin. The main objective of this study was to assess
MAGE-A3 mRNA as a new molecular marker of micro-
metastatic breast cancer in SLN of breast cancer patients.
Although MAGE-A3 has previously been detected in primary
breast cancer, detection of breast cancer metastatic to the lymph
nodes with MAGE-A3 has not been studied in large groups of
patients (Russo et al, 1995). 
MATERIALS AND METHODS 
Sentinel node frozen section preparation 
Surgical specimens were obtained after informed consent in
consultation with the surgeon and pathologist. All tissues were
collected and dissected under stringent sterile conditions to
prevent RNA contamination. SLN were obtained from 77 consec-
utive AJCC Stage I–IIIA breast cancer patients undergoing SLN
dissection, as previously described (Giuliano et al, 1994, 1995,
1997). Among these 77 patients, 60 were diagnosed with infil-
trating ductal carcinoma (IDC), 10 with infiltrating lobular carci-
noma (ILC), and 7 with other breast cancer variants. Primary
tumour samples from these same 77 patients were not obtained, as
most had very early stage disease, and many were referred
following initial biopsy at other institutions. Institutional review
board approval was obtained for human subject usage of lymph
nodes obtained from all patients. SLN were prepared for
histopathological examination, RT-PCR and Southern blot
analysis as depicted in Figure 1. Each SLN was bisected, and an
imprint slide was prepared from the tissue surface, and then
stained with Diff-Quick I & II (Dade International, Miami, FL)
(Reyes et al, 1998). An 8-µ m section of tissue from the bisected
frozen SLN was also stained with Diff-Quik, and used in the
pathologist’s intraoperative evaluation. 6 consecutive adjacent
frozen sections were then cut on the cryostat, to a thickness of 12
µ m each, and immediately stored at –80˚C until used in the RT-
PCR assay. An additional 8-µ m frozen section of tissue was then
examined by Diff-Quik staining. If tumour cells were identified in
the SLN by Diff-Quik staining, a complete axillary lymph node
dissection was then performed. The bisected node was then placed
in 10% formalin, embedded in a paraffin block, and a 4-µ m-thick
section was examined by light microscopy following H&E
staining. If no metastases were identified by H&E staining alone,
an adjacent 4-µ m section was evaluated with anti-cytokeratin IHC.
Anti-cytokeratin IHC was performed with a cocktail containing
antibodies (MAK-6; Ciba-Corning, Alameda, CA) recognizing
cytokeratins (CK)-8, 14, 15, 16, 18 and 19, using an automated
immunoperoxidase staining processor (Ventana ES; Ventana
Medical Systems, Inc, Tucson, AZ) (Turner et al, 1997, 1999).
This permanent section evaluation was performed at 2 different
levels, separated by approximately 40 µ m. The portion of the SLN
remaining after this extensive analysis was preserved in the event
that further histopathological examination was necessary. 
RNA-positive and -negative controls 
Six breast cancer cell lines were used as positive controls. The
breast cancer cell lines MCF-7, BT-20 and MDA-MB-231 were
obtained from the ATCC (Rockville, MD) and cultured according
to the manufacturer’s instructions. The 734B line is an established
subclone of MCF-7. The cell lines JWCI BM-1 and JWCI JM-1
were established from primary invasive ductal carcinoma and
characterized as breast cancer cell lines at JWCI (Hoon et al, 1996;
Bostick et al, 1998c). All 6 cell lines were grown in RPMI 1640
(Gemini Bioproducts, Calabasas, CA) plus 10% fetal calf serum
(heat inactivated), penicillin and streptomycin (GIBCO, Grant
Island, NY), in culture flasks and passaged as previously described
(Bostick et al, 1998a). 
Lymph nodes obtained from 10 patients with benign surgical
diseases were confirmed to be tumour-free by H&E staining and
light microscopy, and were used for RT-PCR analysis as negative
controls. 10 ml of blood collected from healthy donor volunteers
in sodium citrate-containing tubes, as previously described, were
also used as negative controls for the RT-PCR assay (Bostick et al,
1998a). The blood was centrifuged using a hypotonic density
gradient solution, and nucleated cells (peripheral blood mononu-
clear cells; PBMC) in the blood were collected for RNA isolation
as previously described (Bostick et al, 1998a). 
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Figure 1 Schematic diagram of SN preparation for histopathology and RT-
PCR analysis: (A) Bisecting of SN with scalpel; (B) Sectioning frozen
bisected SN; (C) Frozen sections serially cut for different assays 1342 RA Wascher et al
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RNA preparation 
TRI-REAGENT (Molecular Research Center, Cincinnati, OH)
was used to isolate total RNA from the cell lines, frozen section
SLN, non-sentinel nodes, normal lymph nodes and blood
following the manufacturer’s instructions. RNA was then precipi-
tated after adding 500 µ l of isopropanol followed by storage at
–30˚C for 12 h. The sample tube was then centrifuged at 14 000 g
at 4˚C for 10 min. The sample was then washed with 75% ethanol,
vacuum-dried, and resuspended in 10 mM Tris-HCl with 0.1 mM
EDTA solution (pH 8). The concentration, purity and amount of
total RNA were then determined by UV spectrophotometry. The
integrity of all RNA samples was verified by performing RT-PCR
with the housekeeping gene porphobilinogen deaminase (PBGD),
and was confirmed by ethidium bromide gel electrophoresis
(Bostick et al, 1999). If a sample did not express PBGD mRNA,
the RNA was considered inadequate and no further analysis was
performed. Tissue processing, RNA extraction, RT-PCR assay set-
up, and post-PCR product analysis were carried out in separate
designated rooms and buildings to prevent cross-contamination as
previously reported (Bostick et al, 1998a, 1999). 
Oligonucleotide primers and probes 
The primer sequence for MAGE-A3 was as follows: 5′ primer: 5′ -
GAA GCC GCC CCA GGC TCG-3′ and 3′ primer: 5′ -GGA GTC
CTC ATA GGA TTG GCT CC-3′ . The MAGE-A3 RT-PCR cDNA
product produced with this primer set was 423 base pairs in size
(Hoon et al, 1995b). Purified fragments of the cDNA products
amplified with MAGE-A3 primer sets were labelled with digoxi-
genin (Boehringer Mannheim, La Jolla, CA) and used as DNA
probes in the Southern blot assay (Bostick et al, 1998a). The
PBGD primers have been previously described (Finke et al, 1993). 
RT-PCR assay 
The RT-PCR assay was carried out as previously described
(Bostick et al, 1999). RT was performed on 1 µ g of total RNA for
each RT reaction, as specified for Moloney murine leukaemia
virus-reverse transcriptase (Promega, Madison, WI). The RNA
was incubated at 70˚C for 5 min and then put on ice before addi-
tion of RT reaction reagents. Molecular biology grade water was
used in place of RNA as a negative control for all RT reactions.
The RNA with RT reagents added was incubated at 37˚C for 2 h,
followed by heating at 95˚C for 5 min. All RT reactions were
carried out with oligo-dT priming. The PCR conditions were as
follows: 1 cycle of denaturing at 95˚C for 5 min, followed by 35
cycles of 95˚C for 1 min, 55˚C for 1 min, and 72˚C for 1 min
before a final extension at 72˚C for 10 min. RT-PCR optimal
conditions were accomplished using an Omni thermocycler
(Hybaid, Middlesex, UK). The RT-PCR cDNA products run on
2% agarose gel were alkaline-denatured, and Southern blotting
was performed as previously described (Bostick et al, 1998a). The
MAGE-A3 cDNA probe was developed from the RT-PCR cDNA
products and labelled with digoxigenin. Specific binding was
detected using anti-digoxigenin, alkaline phosphatase-conjugated
antibody (Boehringer Mannheim, Indianapolis, IN) as described
by the manufacturer. Any discrepancies or faint signals in
Southern blotting were repeated for verification. In each experi-
ment set-up, samples of RT-PCR reagents without mRNA, and
previously tested mRNA marker-negative healthy donor blood
cells and lymph nodes were used as negative controls. Previously
tested positive tumour cell lines or tumour biopsy specimens were
included in the assay as positive RT-PCR and Southern blot
controls. If known reagent control samples were different than
expected, the results were discarded and the assay was repeated
with new reagents. Results in the analysis of all specimens were
determined to be positive only after verification by Southern blot-
ting. 
RESULTS 
MAGE-A3 mRNA expression in specimens 
Breast cancer cell lines, primary breast cancer tumours and blood
and lymph nodes from healthy volunteers were used as RT-PCR
controls. 4 of 6 (67%) breast cancer cell lines and 5 of 10 (50%)
primary breast cancers assessed expressed MAGE-A3 mRNA
(Table 1). A positive result was indicated by a 423-bp size cDNA
band detected by RT-PCR and Southern blotting (referred from
this point as RT-PCR assay) (Figure 2). Donor blood cells from 25
healthy volunteers (15 females) were evaluated for MAGE-A3
mRNA marker expression. MAGE-A3 mRNA was not detected in
any of the donor blood cells from these healthy volunteers. After
informed consent, normal lymph nodes (confirmed histopatholog-
ically) were obtained from 10 patients undergoing non-cancer
surgery (e.g., cholecystectomy, hernia repair). MAGE-A3 mRNA
was not expressed in any of these normal lymph nodes. This high
frequency of MAGE-A3 mRNA expression in breast cancer
tumour cells, and the lack of expression in normal controls, led us
to further investigate its clinicopathologic utility for the detection
of metastatic cells in the SLN of breast cancer patients. 
Sensitivity of RT-PCR assay 
Total RNA was isolated from breast carcinoma cell lines and seri-
ally diluted for the RT-PCR assay to determine its sensitivity. An in
Table 1 MAGE-A3 mRNA marker expressiona
RNA source n MAGE-A3 mRNA 
marker expression (%) 
Breast cancer cell lines 6 4 (67) 
Primary breast tumours 10 5 (50) 
Normal non-cancer donor bloods 25 0 
Normal non-cancer lymph nodes 10 0 
amRNA marker expression refers to RT-PCR and Southern blot analysis (all
specimens assessed were mRNA-positive for PBGD by ethidium bromide
gel analysis). 
1     2    3   4   5    6     7      8      9   10    11     12    13     14
423 bp
Figure 2 Representative examples of MAGE-A3 mRNA expression by the
RT-PCR assay. Lanes 1 and 2 correspond to primary breast tumours; lane 3,
H2O (negative control); lanes 4 and 5, normal PBL (negative controls); lanes
6–10, representative frozen sections of SN; lanes 11 and 12, non-SLN; and
lanes 13 and 14, breast cancer cell lines MCF-7 and JWCI JM-1,
respectively. All RT-PCR assays were performed with 1 µ g RNA, and cDNA
products were equally loaded on the gel for Southern blotting. All specimens
assessed were mRNA positive for PBGD by ethidium bromide gel
electrophoresis analysis. RT-PCR analysis of breast cancer sentinel nodes 1343
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vitro model was assessed whereby serially diluted (1 to 105) breast
cancer cells (MCF-7) were mixed with 107 normal donor PBMC.
The detection sensitivity of the assay was approximately 1–5
breast cancer cells in 107 PBMC (data not shown). 
Histopathology of sentinel lymph nodes 
The SLN (n = 121) from 77 AJCC stage I–IIIA breast cancer
patients undergoing SLND were analysed by H&E. Nodes that
appeared negative by H&E evaluation for tumour cells were then
assessed by IHC (Table 2). In 48 of 121 (40%) SLN, tumour cells
were detected by histopathological means (H&E or IHC) and 35 of
77 (45%) patients had histopathologically positive SLN. The
remaining 73 of 121 (60%) SLN did not contain detectable tumour
cells by histopathological analysis (H&E or IHC). MAGE-A3
mRNA was expressed in 22 of 48 (46%) SLN that were positive
for tumour by H&E or IHC (Table 2). MAGE-A3 mRNA was also
detected in 28 of 73 (38%) histopathologically negative (by H&E
or IHC) SLN. Overall, 41 of 77 (53%) of patients and 50 of 121
(41%) SLN were positive for tumour cells by MAGE-A3 mRNA
expression. 
Correlation of MAGE-A3 mRNA expression with
prognostic factors 
MAGE-A3 mRNA expression in the SLN was evaluated for corre-
lation with currently accepted prognostic factors for breast carci-
noma. MAGE-A3 mRNA was expressed in the SLN of 10 of 10
(100%) patients with ILC compared to only 30 of 60 (50%) SLN
in patients with IDC, which was significant (P < 0.001, Fisher’s
exact test). The mean Bloom–Richardson score was 6.5 ± 1.6 for
SLN that expressed MAGE-A3 mRNA compared to 5.6 ± 1.6 for
SLN that did not express MAGE-A3 mRNA, and approached
significance (P = 0.07). The SLN of 12 of 17 (71%) patients with
poorly differentiated tumours expressed MAGE-A3 mRNA
compared with the SLN of 4 of 12 (33%) patients with well-differ-
entiated tumours (P = 0.13). This tumour grade correlation with
MAGE-A3 expression did not reach statistical significance, most
likely due to the small sample size of patients with either poorly or
well differentiated tumours. 9 of 12 (75%) SLN from oestrogen
receptor (ER)-negative primary tumours expressed MAGE-A3,
while 30 of 62 (48%) SLN from ER-positive tumours expressed
MAGE-A3, though this association also did not quite reach statis-
tical significance (P = 0.9). Age, menopausal status, family
history, tumour size, oestrogen receptor status, progesterone
receptor status, S-phase content, tumour ploidy, HER-2/neu status,
intraductal extent of tumour, and angiolymphatic invasion did not
appear to correlate with the MAGE-A3 RT-PCR status of the SLN. 
DISCUSSION 
The ideal mRNA tumour marker for RT-PCR evaluation is one
that is expressed frequently in cancer cells, but not in non-cancer
cells of the tissue/fluid compartment being assessed. The detection
of micrometastatic breast cancer cells by RT-PCR analysis has
been limited by the lack, thus far, of mRNA markers specific to
breast carcinoma. In this study, the MAGE-A3 mRNA marker was
assessed as a candidate molecular marker for detecting breast
cancer in SLN because of its high degree of specificity for breast
cancer cells, and its absence of expression in normal cells in the
breast, lymph nodes and blood (Fujie et al, 1997). 
During conventional H&E histopathological evaluation of
lymph nodes, the nodes are cut into a limited number of sections
prior to microscopic evaluation. There are, however, several
methods of increasing the histopathological yield of lymph nodes.
The yield of tumour cell detection in the axillary lymph nodes can
be increased over standard H&E histopathological evaluation by
as much as 33% merely by cutting multiple thin serial sections
(International (Ludwig) Breast Cancer Study Group, 1990; Neville
et al, 1992). 
At present, there is considerable controversy regarding the
reproducibility and accuracy of IHC, as well as the clinical signif-
icance of IHC-positive lymph nodes draining the primary tumour
site (Carter et al, 2000; Fitzgibbons et al, 2000; Hammond et al,
2000). These concerns have been amplified by the recent finding
that benign epithelial cells can be identified in the axillary lymph
nodes of patients following breast biopsy, and which appear to be
translocated to the node following surgical manipulation of the
breast during initial biopsy (Carter et al, 2000). Irrespective of the
debate about the accuracy and reproducibility of IHC, the presence
of such benign mammary epithelial cells in the axillary nodes of a
patient undergoing breast cancer surgery would likely be inter-
preted as occult tumor cell(s) by IHC assays against cytokeratins.
Thus the use of MAGE-A3 RT-PCR, given that MAGE-A3 is not
expressed in normal mammary epithelial cells, may increase the
specificity and accuracy of evaluating SLN for micrometastases
over IHC, as IHC stains for cytokeratins will demonstrate a posi-
tive result for both benign and malignant epithelial cells.
Additionally, RT-PCR of processed SLN tissue may obviate the
potential for false negatives that occur due to sampling errors
during conventional histopathological processing and analysis. 
In our study, 33 of 121 (27%) SLN were identified as positive
for tumour cells by H&E, and 15 (45%) of these 33 SLN were
positive for MAGE-A3 expression. SLN that were H&E negative
accounted for 88 of 121 (73%), and 35 of these 88 (40%) H&E-
negative SLN were RT-PCR positive for MAGE-A3. This is in
contrast to the 15 (17%) of 88 H&E-negative SLN upstaged by
IHC alone in this study. A total of 15 of 121 (12%) SLN were
H&E-negative and IHC-positive, and 7 of these 15 (47%) SLN
were positive for MAGE-A3. Among SLN histopathologically
negative by both H&E and IHC, 28 of 73 (38%) were positive
based upon MAGE-A3 mRNA expression. 
The direct comparison of RT-PCR results and standard
histopathological results (e.g., H&E and IHC) for the same tumour
specimens can be problematic. The expression of specific tumour-
associated mRNA markers is heterogeneous within a population of
primary or metastatic cancer cells. This factor accounts for the
commonly observed pattern of expression of individual specific
tumour markers in a population of tumour cells, whereby only a
subset of cells derived from primary and metastatic tumours will
Table 2 MAGE-A3 mRNA expression and histopathology of SN 
SN histopathology Number of SN RT-PCR positive 
by H&E/IHCa for MAGE-A3 (%) 
H&E (+) 33 15 (45) 
H&E (–) 88 35 (40) 
H&E (–)/IHC (–) 73 28 (38) 
H&E (–)/IHC (+) 15 7 (47) 
aH&E/IHC (+) refers to positive for either H&E staining and/or IHC analysis;
H&E/IHC (–) refers to negative for both methods of histopathological
analysis. 1344 RA Wascher et al
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express such markers. Thus the presence or absence of tumour-
associated molecular markers does not always directly correspond
to the standard histopathological features used to confirm tumour
cell presence. 
Patients with micrometastases detected by histopathological
and/or RT-PCR analysis may represent a subgroup at increased
risk of disease relapse. Approximately 30–40% of patients with no
histopathological evidence of metastases to the axillary basin will
subsequently relapse with distant disease (Giuliano et al, 1994,
1995; Hellman, 1994). This may in part be due to undetected
micrometastatic disease in lymph nodes, haematogenous spread,
and/or clinically undetectable disseminated disease at the time of
presentation. At the same time, patients who have histopathologi-
cally positive SLN do not all go on to develop disseminated
disease, as individual tumour cell characteristics and host factors
likely play a crucial role in deterring circulating tumour cells from
forming successfully established metastatic tumours. Long-term
prospective studies should determine if breast cancer patients with
lymph node micrometastases, detected by H&E, IHC or by RT-
PCR molecular assays, are at increased risk of subsequent disease
relapse. The American College of Surgeons Oncology Group
Z0010 trial (PI: Armando Giuliano, JWCI) is currently underway,
and should provide meaningful answers to such questions within
the next 5–10 years. 
In terms of the prognostic significance of MAGE-A3 expression
in the SLN of breast cancer patients, we have recently demon-
strated that the presence of MAGE-A3 in the SLN of patients with
melanoma, combined with other melanoma RT-PCR mRNA
markers, significantly correlated with a greater risk of disease
recurrence (Bostick et al, 1999). If breast cancer SLN micrometas-
tases possess the same prognostic correlation with disseminated
disease as appears to be the case with melanoma, then the detec-
tion of MAGE-A3 in the histopathologically negative SLN of
breast cancer patients may prove to be of significant prognostic
importance as well. As a tertiary referral centre for breast cancer,
73 of the 77 (95%) of our study patients had AJCC stage I or II
breast cancer at the time of inclusion in the study, with a mean
follow-up of just over 5 years to date. In view of the frequently
prolonged natural history of breast cancer metastasis, meaningful
prognostic correlation of clinical outcome with MAGE-A3 SLN
status cannot be addressed by this study at this time. However, as
of June 2001, follow-up information was available for 65 of the 76
(86%) patients who underwent resection of their primary tumours
and SLN ≥ 5 years ago. Of these 65 patients, one has developed
spinal metastasis (AJCC stage I at initial diagnosis) and her SLN
was positive for MAGE-A3. A second patient is currently pending
biopsy for a highly suspicious breast ultrasound obtained at follow
up, and her SLN was MAGE-A3 positive. A third patient is
presently being evaluated for a newly elevated CA 27.29 level
(stage IIA at initial diagnosis), but she is without clinically or radi-
ographically evident disease, and her SLN was negative for
MAGE-A3. The remaining 62 patients are presently without clin-
ical, radiographic or laboratory evidence of disease at this time. 
An interesting finding in this study was that expression of
MAGE-A3 in the SLN was significantly more common in patients
with ILC than in IDC (P < 0.001, Fisher’s exact test). SLN expres-
sion of MAGE-A3 was also correlated with a higher
Bloom–Richardson score, approaching statistical significance 
(P = 0.07, Wilcoxon rank sums test). This finding is consistent
with our previous studies which have demonstrated that tumours
with higher Bloom–Richardson (BR) scores are at greater risk of
relapse than tumours receiving low BR scores (Bostick et al,
1998c). Although the overall clinical prognosis is similar for both
ILC and IDC, there is a known increased risk of bilateral and
multifocal disease with ILC. Moreover, there are recent data that
suggest that true histopathologic, genetic and clinical prognostic
differences exist between ILC and IDC. For example, there is
evidence that ILC variants may have a different prognostic
outcome as compared to IDC (Toikkanen et al, 1997; Bentz et al,
1998; Sinha et al, 2000). Distinctive patterns of chromosomal
imbalance may also be found when comparing ILC to IDC
(Richard et al, 2000), as well as histopathological differences (Lee
et al, 1998; Prasad et al, 1998). The findings of our study may be
further evidence that significant phenotypic differences exist
between these 2 invasive breast cancer variants, despite their
otherwise similar clinical outcomes. 
In view of the known immunogenicity of MAGE antigens,
patients with breast tumours that express MAGE-A3 may poten-
tially benefit from active-specific immunotherapy targeted to
MAGE-A3 protein epitopes. Active-specific immunotherapies
used to date are in the form of vaccines with MAGE-A3 peptides,
MAGE-A3 gene vaccines, or dendritic cells pulsed with MAGE-
A3 peptide (Okamoto et al, 1997; Thurner et al, 1999; Weber et al,
1999). Post-surgery adjuvant vaccination may be useful in patients
who have MAGE-A3-expressing metastatic breast tumour cells to
reduce the incidence of disease recurrence, or to control existing
subclinical disease progression. Adjuvant vaccine therapy in high-
risk clinically disease-free patients provides a non-toxic mainte-
nance therapy that may prolong or prevent disease recurrence
(Pantel et al, 1999). Thus, MAGE-A3 RT-PCR assay for SLN may
find relevance in the clinic in several ways, to include the moni-
toring of patients during treatment; the identification of patients
likely to benefit from active-specific immunotherapy with MAGE-
A3 related products; and/or the assessment of patients at poten-
tially high risk for disease recurrence. 
In terms of future investigation, a logical next step would be to
compare the expression of MAGE-A3 in both the primary tumours
and their associated SLN. The continued follow up of our study
patients may also show a correlation between SLN positive for
MAGE-A3 and clinical prognosis, which is not evident now at just
5 years of follow up in these stage I and II breast cancer patients.
Additionally, future follow-up data from patients included in this
study may also add important prognostic data that are not currently
available. 
In summary, we have shown that the MAGE-A3 mRNA RT-
PCR assay may have a role in the detection of occult tumour cells
in the SLN of breast cancer patients. The detection of this mRNA
marker indicates a greater likelihood of micrometastatic disease
presence, as it is expressed in at least 50% of breast cancer
tumours, but not in benign mammary cells, lymph nodes or blood.
Long-term follow up of patients with SLN positive for MAGE-A3
mRNA expression will yield additional important data regarding
the correlation between the presence of this marker in the SLN and
clinical prognosis. There is also intriguing evidence of differences
in the expression frequency of MAGE-A3 between ILC and IDC
tumours, which adds to the growing evidence that these 2 breast
cancer subtypes may indeed be distinctive from each other in clin-
ically significant respects. Finally, the finding that approximately
one-half of breast tumours express MAGE-A3 may have value in
stratifying patients to receive active-specific immunotherapy
against MAGE-A3 epitopes in prospective trials, and to follow
their responses to these and other therapies. RT-PCR analysis of breast cancer sentinel nodes 1345
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